ATAD2 and pancreatic neoplasm: ATAD2 deletion inhibited the invasive and migratory functions of pancreatic cancer cells (PCCs) and made them susceptible to gemcitabine, and ATAD2 gene knockout inhibited the non-anchored growth of PCCs in vitro [31,113].